Clinical predictive value of renalase in post-ERCP pancreatitis

Thiruvengadam Muniraj; Gary Desir; Fred S Gorelick; Xiaojia Guo; Maria M Ciarleglio; Yanhong Deng; Priya A Jamidar; James Farrell; Harry R Aslanian; Loren Laine

doi:10.1016/j.gie.2023.12.020

Clinical predictive value of renalase in post-ERCP pancreatitis

Gastrointest Endosc. 2024 May;99(5):822-825.e1. doi: 10.1016/j.gie.2023.12.020. Epub 2023 Dec 14.

Affiliations

¹ Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
² Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Medicine, VA Connecticut Healthcare System, West Haven, Connecticut, USA.
³ Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.

PMID: 38103747
DOI: 10.1016/j.gie.2023.12.020

Abstract

Background and aims: Plasma levels of renalase decrease in acute experimental pancreatitis. We aimed to determine if decreases in plasma renalase levels after ERCP predict the occurrence of post-ERCP pancreatitis (PEP).

Methods: In this prospective cohort study conducted at a tertiary hospital, plasma renalase was determined before ERCP (baseline) and at 30 and 60 minutes after ERCP. Native renalase levels, acidified renalase, and native-to-acidified renalase proportions were analyzed over time using a longitudinal regression model.

Results: Among 273 patients, 31 developed PEP. Only 1 PEP patient had a baseline native renalase >6.0 μg/mL, whereas 38 of 242 without PEP had a native renalase > 6.0 μg/mL, indicating a sensitivity of 97% (30/31) and specificity of 16% (38/242) in predicting PEP. Longitudinal models did not show differences over time between groups.

Conclusions: Baseline native renalase levels are very sensitive for predicting PEP. Further studies are needed to determine the potential clinical role of renalase in predicting and preventing PEP.